$6.79
1.65% (Daily)
Market Cap
$342.16M
Revenue
$212.00M
Rank by MCap
#1437
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alan H. Auerbach
Headquarters
Los Angeles, CA
Employees
172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for ...
Loading chart…